Skip to main content

Table 1 Participant overview

From: Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer’s disease

 

Total cohort

Control

MCI

AD

Urine

    

 Participants

556

171

209

176

 Male/female

269/287

83/88

95/114

91/85

 Mean age (SD)

76.24 (5.76)

75.85 (5.17)

76.33 (6.03)

76.53 (5.99)

 MMSE score

25.67 (4.59)

28.73 (1.92)

26.86 (2.75)

21.17 (4.87)

 CDR

0.56 (0.51)

0.07 (0.18)

0.49 (0.08)

1.10 (0.54)

 Reported SSRI medication

43

4

16

23

Serum

    

 Participants

354

86

165

103

 Male/female

165/189

44/42

71/94

50/53

 Mean age

76.95 (6.13)

75.97 (5.67)

77.50 (6.49)

76.91 (5.84)

 MMSE score

25.57 (4.37)

28.80 (1.99)

26.73 (2.24)

21.06 (4.79)

 CDR

0.59 (0.54)

0.04 (0.16)

0.49 (0.11)

1.16 (0.55)

 Reported SSRI medication

30

1

11

18

  1. Overview of the sample cohort used in the study. SSRI selective serotonin reuptake inhibitor, MCI mild cognitive impairment, AD Alzheimer’s disease, MMSE Mini-Mental State Examination score, CDR Clinical Dementia Rating